---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-017615"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:23:48.193707+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunocore Q1: KIMMTRAK revenue $93.9M (+33% YoY); net income $5M vs loss year ago

## Summary
- KIMMTRAK net sales $93.9M, up 33% YoY; US $56.6M, Europe $32.8M (incl $6M favorable adjustments), intl $4.5M.
- Net income $5.0M vs net loss $24.4M in Q1 2024; diluted EPS $0.10 vs ($0.49).
- Phase 3 TEBE-AM (cutaneous melanoma) enrollment on track to complete in 1H 2026; PRISM-MEL-301 dose selection expected 2H 2025.
- HIV candidate IMC-M113V showed viral control in 3 of 15 evaluable patients at CROI; dose escalation continuing.
- Cash and securities $837M at March 31, 2025, up from $820.4M at Dec 31, 2024.

## SEC filing metadata
- accession: 0001140361-25-017615
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036125017615/0001140361-25-017615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036125017615/ef20048471_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-017615
- JSON: https://secwatch.observer/filing/0001140361-25-017615.json
- Plain text: https://secwatch.observer/filing/0001140361-25-017615.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.